
Opko Health (OPK) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
150.0M
Gross Profit
42.6M
28.42%
Operating Income
-67.2M
-44.79%
Net Income
-67.6M
-45.09%
EPS (Diluted)
$-0.10
Balance Sheet Metrics
Total Assets
2.1B
Total Liabilities
816.7M
Shareholders Equity
1.3B
Debt to Equity
0.62
Cash Flow Metrics
Operating Cash Flow
-13.8M
Free Cash Flow
-37.7M
Revenue & Profitability Trend
Opko Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 713.1M | 863.5M | 1.0B | 1.8B | 1.4B |
Cost of Goods Sold | 494.6M | 545.4M | 716.0M | 1.2B | 894.4M |
Gross Profit | 218.5M | 318.1M | 288.2M | 581.5M | 541.0M |
Gross Margin % | 30.6% | 36.8% | 28.7% | 32.8% | 37.7% |
Operating Expenses | |||||
Research & Development | 105.2M | 89.6M | 73.9M | 76.8M | 75.3M |
Selling, General & Administrative | 304.2M | 300.6M | 372.7M | 468.9M | 355.6M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 409.4M | 390.2M | 446.6M | 545.7M | 430.9M |
Operating Income | -273.6M | -158.1M | -246.1M | -14.5M | 53.7M |
Operating Margin % | -38.4% | -18.3% | -24.5% | -0.8% | 3.7% |
Non-Operating Items | |||||
Interest Income | 8.4M | 4.0M | 2.0M | 28.0K | 152.0K |
Interest Expense | 47.5M | 13.5M | 12.1M | 18.9M | 21.9M |
Other Non-Operating Income | 302.2M | -16.7M | -135.3M | 19.3M | 16.7M |
Pre-tax Income | -10.4M | -184.3M | -391.5M | -14.0M | 48.7M |
Income Tax | 42.8M | 4.4M | -63.5M | 15.5M | 17.6M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 36.2% |
Net Income | -53.2M | -188.9M | -328.4M | -30.1M | 30.6M |
Net Margin % | -7.5% | -21.9% | -32.7% | -1.7% | 2.1% |
Key Metrics | |||||
EBITDA | 39.9M | -65.8M | -291.3M | 49.5M | 151.9M |
EPS (Basic) | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 |
EPS (Diluted) | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 |
Basic Shares Outstanding | 694019535 | 751716915 | 719060942 | 648077716 | 640655290 |
Diluted Shares Outstanding | 694019535 | 751716915 | 719060942 | 648077716 | 640655290 |
Income Statement Trend
Opko Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 431.9M | 95.9M | 153.2M | 134.7M | 72.2M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 118.0M | 123.4M | 127.3M | 259.6M | 286.3M |
Inventory | 56.8M | 65.7M | 74.1M | 86.5M | 132.3M |
Other Current Assets | 10.7M | 7.7M | 6.3M | 6.2M | 5.3M |
Total Current Assets | 662.1M | 309.5M | 394.5M | 823.0M | 523.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 54.0M | 68.1M | 38.7M | 44.2M | 37.7M |
Goodwill | 1.9B | 2.1B | 2.2B | 2.0B | 2.4B |
Intangible Assets | 811.6M | 935.3M | 1.0B | 911.9M | 1.1B |
Long-term Investments | 3.0K | 2.0K | 28.0K | 16.0K | 74.0K |
Other Non-Current Assets | 18.5M | 9.1M | 8.7M | 9.5M | 10.1M |
Total Non-Current Assets | 1.5B | 1.7B | 1.8B | 1.6B | 1.9B |
Total Assets | 2.2B | 2.0B | 2.2B | 2.4B | 2.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 47.1M | 69.7M | 67.0M | 82.0M | 100.9M |
Short-term Debt | 29.3M | 43.1M | 51.0M | 28.6M | 36.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | 28.2M | - |
Total Current Liabilities | 193.1M | 200.1M | 213.5M | 330.0M | 375.5M |
Non-Current Liabilities | |||||
Long-term Debt | 475.1M | 283.4M | 254.5M | 226.2M | 258.4M |
Deferred Tax Liabilities | 140.8M | 126.8M | 126.4M | 148.5M | 137.2M |
Other Non-Current Liabilities | 11.5M | 12.2M | 11.0M | 9.7M | 29.8M |
Total Non-Current Liabilities | 641.7M | 422.4M | 392.1M | 384.6M | 426.0M |
Total Liabilities | 834.8M | 622.5M | 605.6M | 714.6M | 801.5M |
Equity | |||||
Common Stock | 7.0M | 7.8M | 7.8M | 6.9M | 6.7M |
Retained Earnings | -2.1B | -2.0B | -1.8B | -1.5B | -1.5B |
Treasury Stock | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.4B | 1.4B | 1.6B | 1.7B | 1.7B |
Key Metrics | |||||
Total Debt | 504.4M | 326.6M | 305.5M | 254.8M | 294.6M |
Working Capital | 469.0M | 109.4M | 181.0M | 493.0M | 147.7M |
Balance Sheet Composition
Opko Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -53.2M | -188.9M | -328.4M | -30.1M | 30.6M |
Depreciation & Amortization | 98.2M | 105.3M | 108.7M | 78.7M | 85.4M |
Stock-Based Compensation | 11.0M | 11.4M | 18.5M | 13.6M | 8.9M |
Working Capital Changes | -16.5M | 27.1M | 133.4M | 13.2M | -179.4M |
Operating Cash Flow | 67.1M | -41.9M | -139.6M | 101.4M | -32.0M |
Investing Activities | |||||
Capital Expenditures | 242.0K | 2.7M | 2.0M | 66.0M | 245.0K |
Acquisitions | 210.4M | -5.0M | -1.8M | -6.0M | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | 166.6M | 364.0K | 115.4M | 8.1M | 15.1M |
Investing Cash Flow | 377.2M | -1.9M | 115.6M | 68.1M | 15.4M |
Financing Activities | |||||
Share Repurchases | -90.2M | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 939.4M | 671.7M | 1.1B | 1.7B | 1.1B |
Debt Repayment | -651.4M | -682.7M | -1.0B | -1.7B | -1.1B |
Financing Cash Flow | 184.4M | -11.0M | 23.7M | -22.7M | -71.7M |
Free Cash Flow | -208.5M | -44.5M | -119.8M | 6.2M | 5.8M |
Net Change in Cash | 628.7M | -54.9M | -251.0K | 146.8M | -88.4M |
Cash Flow Trend
Opko Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-17.13
Forward P/E
-4.72
Price to Book
0.82
Price to Sales
1.64
PEG Ratio
-4.72
Profitability Ratios
Profit Margin
-26.68%
Operating Margin
-38.25%
Return on Equity
-13.16%
Return on Assets
-8.46%
Financial Health
Current Ratio
3.41
Debt to Equity
30.51
Beta
1.19
Per Share Data
EPS (TTM)
$-0.26
Book Value per Share
$1.66
Revenue per Share
$0.96
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
opk | 1.1B | -17.13 | 0.82 | -13.16% | -26.68% | 30.51 |
Thermo Fisher | 184.1B | 28.17 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 146.0B | 43.29 | 2.79 | 6.68% | 14.21% | 35.45 |
Twist Bioscience | 1.7B | -7.35 | 3.53 | -17.58% | -23.52% | 19.48 |
Neogen | 1.2B | 865.00 | 0.59 | -41.88% | -122.06% | 44.14 |
Grail | 1.1B | -0.49 | 0.49 | -17.68% | -62.12% | 2.69 |
Financial data is updated regularly. All figures are in the company's reporting currency.